Journal
ONCOLOGIST
Volume 13, Issue 1, Pages 16-24Publisher
OXFORD UNIV PRESS
DOI: 10.1634/theoncologist.2007-0199
Keywords
insulin-like growth factor-I; insulin-like growth factor-II; insulin-like growth factor-I receptor; breast cancer; review
Categories
Ask authors/readers for more resources
The insulin-like growth factor signaling pathway is important in many human cancers based on data from experimental models as well as epidemiological studies. Important therapies targeted at this pathway have been or are being developed, including monoclonal antibodies to the insulin-like growth factor-I receptor and small molecule inhibitors of the tyrosine kinase function of this receptor. These investigational therapies are now being studied in clinical trials. Emerging data from phase I trials are encouraging regarding the safety of the monoclonal antibodies. In this manuscript, the rationale for targeting the insulin-like growth factor system is reviewed in addition to a summary of the available clinical trial data.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available